Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309664554> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W4309664554 endingPage "1754" @default.
- W4309664554 startingPage "1754" @default.
- W4309664554 abstract "Context: Immune checkpoint inhibitors combined with chemotherapy are being evaluated in neoadjuvant settings in early triple-negative breast cancer (TNBC).Aim: To evaluate efficacy and safety of checkpoint inhibitors in early TNBC.Methods: Electronic search was done using PubMed, EMBASE, Google Scholar, Cochrane Central Register of Controlled Trials and clinicaltrials.gov to identify relevant articles till October 31, 2020. Clinical trials evaluating checkpoint inhibitors as neoadjuvant therapy in early-stage TNBC were included. Outcomes assessed included pathologic complete response (pCR), event-free survival (EFS), and safety.Statistical Analysis Used: Meta-analysis was conducted using Cochrane review manager (RevMan) version 5.4. Randomized controlled trials (RCTs) were assessed for quality using Cochrane Collaboration risk of the bias assessment tool, version 2.0 (ROB-2). GRADE analysis was done to assess the overall quality of evidence for all outcomes.Results: Out of 116 studies screened, 5 RCTs were included in meta-analysis. Compared to control group, programmed death-1 (PD-1)/programmed death-ligand 1 (PDL-1) inhibitor group was associated with significant increase in rate of pCR (odd ratio [OR] =1.71 [1.38–2.11]; P < 0.00001) and EFS (1.77 [1.21–2.60]; P = 0.003). There was a significant increase in risk of serious adverse events (risk ratio [RR] =1.53 [1.28-1.83]; P < 0.00001), adverse events of special interest (AESI) of any grade (RR: 1.5 [1.34–1.69], P < 0.00001) and grade 3 or higher AESI (RR: 2.8 [1.87–4.19], P < 0.00001) with PD-1/PDL-1 inhibitors compared to control.Conclusions: PD-1/PDL-1 inhibitors in combination with neoadjuvant chemotherapy for early TNBC show significant improvement in pCR irrespective of PDL-1 status and cancer stage." @default.
- W4309664554 created "2022-11-29" @default.
- W4309664554 creator A5007635774 @default.
- W4309664554 creator A5023240564 @default.
- W4309664554 creator A5038940517 @default.
- W4309664554 creator A5050511829 @default.
- W4309664554 creator A5087255064 @default.
- W4309664554 date "2022-01-01" @default.
- W4309664554 modified "2023-10-02" @default.
- W4309664554 title "Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis" @default.
- W4309664554 cites W1555003755 @default.
- W4309664554 cites W1984545852 @default.
- W4309664554 cites W2014179352 @default.
- W4309664554 cites W2066671159 @default.
- W4309664554 cites W2075894019 @default.
- W4309664554 cites W2096027508 @default.
- W4309664554 cites W2100413206 @default.
- W4309664554 cites W2117294447 @default.
- W4309664554 cites W2124060252 @default.
- W4309664554 cites W2155464214 @default.
- W4309664554 cites W2767596067 @default.
- W4309664554 cites W2786816161 @default.
- W4309664554 cites W2946550606 @default.
- W4309664554 cites W2970684805 @default.
- W4309664554 cites W2980166314 @default.
- W4309664554 cites W2989593825 @default.
- W4309664554 cites W2990398119 @default.
- W4309664554 cites W3003627105 @default.
- W4309664554 cites W3005738019 @default.
- W4309664554 cites W3006930853 @default.
- W4309664554 cites W3008792561 @default.
- W4309664554 cites W3010020169 @default.
- W4309664554 cites W3015192582 @default.
- W4309664554 cites W3019350884 @default.
- W4309664554 cites W3087393791 @default.
- W4309664554 cites W3148962211 @default.
- W4309664554 doi "https://doi.org/10.4103/jcrt.jcrt_1867_20" @default.
- W4309664554 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36412440" @default.
- W4309664554 hasPublicationYear "2022" @default.
- W4309664554 type Work @default.
- W4309664554 citedByCount "1" @default.
- W4309664554 countsByYear W43096645542023 @default.
- W4309664554 crossrefType "journal-article" @default.
- W4309664554 hasAuthorship W4309664554A5007635774 @default.
- W4309664554 hasAuthorship W4309664554A5023240564 @default.
- W4309664554 hasAuthorship W4309664554A5038940517 @default.
- W4309664554 hasAuthorship W4309664554A5050511829 @default.
- W4309664554 hasAuthorship W4309664554A5087255064 @default.
- W4309664554 hasBestOaLocation W43096645541 @default.
- W4309664554 hasConcept C121608353 @default.
- W4309664554 hasConcept C126322002 @default.
- W4309664554 hasConcept C143998085 @default.
- W4309664554 hasConcept C151730666 @default.
- W4309664554 hasConcept C168563851 @default.
- W4309664554 hasConcept C197934379 @default.
- W4309664554 hasConcept C2778292576 @default.
- W4309664554 hasConcept C2779343474 @default.
- W4309664554 hasConcept C2780110267 @default.
- W4309664554 hasConcept C44249647 @default.
- W4309664554 hasConcept C530470458 @default.
- W4309664554 hasConcept C71924100 @default.
- W4309664554 hasConcept C82789193 @default.
- W4309664554 hasConcept C86803240 @default.
- W4309664554 hasConcept C95190672 @default.
- W4309664554 hasConceptScore W4309664554C121608353 @default.
- W4309664554 hasConceptScore W4309664554C126322002 @default.
- W4309664554 hasConceptScore W4309664554C143998085 @default.
- W4309664554 hasConceptScore W4309664554C151730666 @default.
- W4309664554 hasConceptScore W4309664554C168563851 @default.
- W4309664554 hasConceptScore W4309664554C197934379 @default.
- W4309664554 hasConceptScore W4309664554C2778292576 @default.
- W4309664554 hasConceptScore W4309664554C2779343474 @default.
- W4309664554 hasConceptScore W4309664554C2780110267 @default.
- W4309664554 hasConceptScore W4309664554C44249647 @default.
- W4309664554 hasConceptScore W4309664554C530470458 @default.
- W4309664554 hasConceptScore W4309664554C71924100 @default.
- W4309664554 hasConceptScore W4309664554C82789193 @default.
- W4309664554 hasConceptScore W4309664554C86803240 @default.
- W4309664554 hasConceptScore W4309664554C95190672 @default.
- W4309664554 hasIssue "6" @default.
- W4309664554 hasLocation W43096645541 @default.
- W4309664554 hasLocation W43096645542 @default.
- W4309664554 hasOpenAccess W4309664554 @default.
- W4309664554 hasPrimaryLocation W43096645541 @default.
- W4309664554 hasRelatedWork W1999292713 @default.
- W4309664554 hasRelatedWork W2114346778 @default.
- W4309664554 hasRelatedWork W2263577673 @default.
- W4309664554 hasRelatedWork W2331329572 @default.
- W4309664554 hasRelatedWork W2338954311 @default.
- W4309664554 hasRelatedWork W2376078656 @default.
- W4309664554 hasRelatedWork W2554176272 @default.
- W4309664554 hasRelatedWork W3044626609 @default.
- W4309664554 hasRelatedWork W3137558222 @default.
- W4309664554 hasRelatedWork W4212933565 @default.
- W4309664554 hasVolume "18" @default.
- W4309664554 isParatext "false" @default.
- W4309664554 isRetracted "false" @default.
- W4309664554 workType "article" @default.